| ATC code N:Nervous system |
|---|
|
| ATCvet only |
|
| Other ATC codes |
ATC code NNervous system is a section of theAnatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by theWorld Health Organization (WHO) for the classification ofdrugs and other medical products.[1][2][3][4]
Codes forveterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example,QN.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
| Inhalational | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection |
| ||||||||||||||
| |||||||||||||||
| Esters by acid |
| ||||||
|---|---|---|---|---|---|---|---|
| Amides | |||||||
| Combinations | |||||||
| |||||||
| Analgesic/abortive |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prophylactic |
| ||||||||||||||||
| |||||||||||||||||
| GABAergics |
| ||||||
|---|---|---|---|---|---|---|---|
| Channel modulators |
| ||||||
| Others |
| ||||||
| |||||||
| Dopaminergics |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticholinergics | |||||||||||
| Others | |||||||||||
| |||||||||||
| D1-like |
| ||||||
|---|---|---|---|---|---|---|---|
| D2-like |
| ||||||
| Typical |
|
|---|---|
| Disputed | |
| Atypical | |
| Others | |
| |
| 5-HT1ARTooltip 5-HT1A receptoragonists | |
|---|---|
| GABAARTooltip GABAA receptorPAMsTooltip positive allosteric modulators |
|
| Gabapentinoids (α2δVDCCblockers) | |
| Antidepressants |
|
| Sympatholytics (Antiadrenergics) | |
| Others | |
| |
| GABAA |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GABAB | |||||||||||||||||||||||||
| H1 |
| ||||||||||||||||||||||||
| α2-Adrenergic | |||||||||||||||||||||||||
| 5-HT2A |
| ||||||||||||||||||||||||
| Melatonin | |||||||||||||||||||||||||
| Orexin | |||||||||||||||||||||||||
| α2δVDCC | |||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
N06BA Centrally actingsympathomimetics | |||||||||
|---|---|---|---|---|---|---|---|---|---|
N06BC Xanthine derivatives | |||||||||
N06BX Other psychostimulants and nootropics | |||||||||
| |||||||||
| AChE inhibitor medications | |
|---|---|
| Other medications | |
| ExperimentalBACE inhibitors | |
| |||||||||||||||||||||||||
Drugs used in treatment ofdrug dependence (N07B) | |
|---|---|
| Nicotine dependence |
|
| Alcohol dependence | |
| Opioid dependence | |
| Benzodiazepine dependence |
|
